Akeso and Summit Therapeutics’ novel bispecific antibody, ivonescimab, has demonstrated a significant improvement in overall survival (OS) in a crucial Phase III clinical trial for first-line non-small cell lung cancer (NSCLC). The positive outcome in the HARMONi-2 trial, which met its key secondary OS endpoint, represents a pivotal moment for the drug as it navigates regulatory reviews in key global markets, notably the United States.
Main Facts
Akeso and Summit Therapeutics announced groundbreaking results from the HARMONi-2 Phase III study, revealing that ivonescimab, when used as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (TPS ≥ 1%), has successfully met its primary secondary endpoint of overall survival (OS). This randomized, double-blind, multicenter trial pitted ivonescimab against Merck & Co.’s blockbuster immunotherapy, Keytruda (pembrolizumab).
The pre-specified interim analysis of OS, meticulously assessed by an Independent Data Monitoring Committee (IDMC), indicated that ivonescimab not only achieved statistical significance but also demonstrated a clinically meaningful improvement compared to Keytruda. This pivotal finding builds upon earlier data from a China-based study with a May 2024 cutoff, which showed a median progression-free survival (PFS) of 11.14 months for ivonescimab versus 5.82 months for Keytruda.
Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody, designed to simultaneously target both the programmed cell death protein 1 (PD-1) pathway, a key mechanism in immune evasion by cancer cells, and the vascular endothelial growth factor (VEGF) pathway, which plays a crucial role in tumor growth and blood vessel formation. This dual mechanism of action is believed to offer a more comprehensive approach to combating cancer.
The positive OS results in the HARMONi-2 trial are particularly significant as they come ahead of a critical regulatory decision in the United States. While ivonescimab has already gained approval in China for NSCLC, it is currently under review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) date set for November 14th. The success in HARMONi-2 is expected to bolster the company’s submission and increase confidence among regulatory bodies.
Chronology of Key Developments
The journey of ivonescimab towards global recognition has been marked by strategic milestones and a growing body of compelling clinical data. Understanding this timeline provides critical context for its current regulatory standing and future potential.
-
2022: Summit Therapeutics entered into a significant agreement with Akeso, pledging up to $5 billion to secure the exclusive rights to develop and commercialize ivonescimab in key global markets, including the United States, Europe, Canada, Japan, Latin America, the Middle East, and Africa. This substantial investment underscored the perceived potential of the bispecific antibody.
-
May 2024: Ivonescimab achieved its first major regulatory milestone with its approval in China for the treatment of NSCLC. This marked a crucial step in validating the drug’s efficacy in a major market and provided early real-world data.
-
May 2024 (Data Cutoff): Earlier data from the China-based study revealed a significant difference in progression-free survival (PFS), with patients treated with ivonescimab experiencing a median PFS of 11.14 months compared to 5.82 months for those treated with Keytruda. This early indicator of efficacy set the stage for the pivotal HARMONi-2 trial.
-
August 2026: Akeso and Summit Therapeutics announced positive results from the HARMONi-GI1 study (NCT06591520), another Phase III trial focusing on patients with advanced biliary tract cancer (BTC). This study also successfully met its overall survival (OS) endpoint, demonstrating ivonescimab’s potential efficacy across different cancer types.
-
Present (HARMONi-2 Trial): The HARMONi-2 trial, a cornerstone of the global development program, reported meeting its key secondary overall survival (OS) endpoint in a pre-specified interim analysis. This result, showing a statistically and clinically meaningful improvement over Keytruda, is a critical development for regulatory submissions in the U.S. and other key markets.
-
November 14, 2026 (PDUFA Date): The U.S. Food and Drug Administration (FDA) is expected to render a decision on the approval of ivonescimab for NSCLC on this date. The recent positive OS data from HARMONi-2 is anticipated to be a significant factor in this review process.
-
Ongoing Research: Beyond HARMONi-2, ivonescimab is also under investigation in other Phase III trials, including HARMONi-7/ AK112-3007, which is evaluating the drug in patients with PD-L1 high-expressing NSCLC. This ongoing research highlights the companies’ commitment to exploring the full potential of ivonescimab across various patient populations and indications.
Supporting Data and Clinical Significance
The success of ivonescimab in the HARMONi-2 trial is underpinned by robust clinical data that addresses critical endpoints for oncology drug development. The dual-action mechanism of ivonescimab, targeting both PD-1 and VEGF, is believed to be instrumental in its observed efficacy.
-
Overall Survival (OS): The primary focus of the HARMONi-2 interim analysis was the OS endpoint. Meeting this goal signifies a direct impact on patient longevity, a paramount concern for both clinicians and patients. The IDMC’s assessment of a "statistically and clinically meaningful improvement" over Keytruda suggests that ivonescimab not only extends life but does so in a way that is medically significant. While specific percentage improvements in OS have not yet been publicly disclosed by Akeso and Summit, analysts from Citi and Evercore have projected that the OS benefit could exceed 30%. This projection, if accurate, would represent a substantial advancement in first-line NSCLC treatment.
-
Progression-Free Survival (PFS): Earlier data from the China-based study provided strong evidence of ivonescimab’s impact on PFS. A median PFS of 11.14 months compared to 5.82 months for Keytruda represents a nearly doubling of the time patients remained without disease progression. PFS is a critical surrogate endpoint that often correlates with OS and is a key indicator of a drug’s ability to control tumor growth.
-
Dual Mechanism of Action: Ivonescimab’s innovative design as a PD-1/VEGF bispecific antibody is a key differentiator. The PD-1 pathway is crucial for immune checkpoint inhibition, allowing the patient’s own immune system to recognize and attack cancer cells. Simultaneously, inhibiting VEGF disrupts the blood supply that tumors need to grow and metastasize. This synergistic approach is hypothesized to overcome resistance mechanisms that can limit the efficacy of single-target therapies.
-
Head-to-Head Superiority: The HARMONi-2 trial is notable for being a direct head-to-head comparison against Keytruda, a well-established and highly successful immunotherapy. Achieving positive OS and PFS outcomes against such a formidable competitor in a first-line setting for NSCLC is a significant clinical achievement. Akeso’s statement that this is the "first Phase III RCT to show a significant positive outcome against Keytruda in this setting" highlights the magnitude of this accomplishment.
-
Broader Efficacy Across Trials: The success in HARMONi-2 is not an isolated event. Ivonescimab has demonstrated dual positive OS and PFS outcomes across multiple Phase III trials when compared against other PD-1/PD-L1 therapies. This consistent performance across different study designs and patient populations strengthens the confidence in ivonescimab’s potential across a broader range of solid tumors, beyond NSCLC. The positive OS outcome in the HARMONi-GI1 study for advanced biliary tract cancer further supports this broader applicability.
Official Responses and Perspectives
The positive clinical results have elicited enthusiastic responses from the leadership at Akeso and Summit Therapeutics, underscoring their confidence in ivonescimab’s therapeutic potential and its role in shaping the future of oncology treatment.
Dr. Yu Xia, President and CEO of Akeso, expressed considerable satisfaction with the latest findings, stating, "We are pleased that the fourth Phase III study of an ivonescimab-based regimen has now demonstrated statistically significant benefit in both OS and PFS. These results further reinforce the clinical value of ivonescimab in the treatment of lung cancer."
Dr. Xia elaborated on the cumulative evidence, emphasizing, "To date, ivonescimab has achieved dual positive OS and PFS outcomes across multiple Phase III head-to-head trials versus PD-1/PD-L1 therapies. This growing body of evidence strengthens our confidence in its potential across a broader range of solid tumours. With its unique dual mechanism of action combining immunotherapy and anti-angiogenesis, we believe ivonescimab offers a more effective treatment option for patients and will contribute meaningfully to the evolving oncology treatment landscape."
The company also highlighted the significance of the HARMONi-2 trial in the broader competitive landscape: "Akeso said that HARMONi-2 is the first Phase III RCT to show a significant positive outcome against Keytruda in this setting." This statement positions ivonescimab as a potential disruptor and a strong challenger to existing standards of care.
While official statements from Summit Therapeutics regarding the HARMONi-2 OS data are awaited, the company’s significant financial commitment in 2022, pledging up to $5 billion to Akeso for global rights, speaks volumes about their belief in the drug’s potential. This substantial investment signals a high level of conviction in ivonescimab’s ability to achieve significant commercial success.
Implications for the Oncology Landscape and Future Outlook
The successful outcome of the HARMONi-2 trial carries substantial implications for the treatment of NSCLC, the broader oncology market, and the strategic positioning of both Akeso and Summit Therapeutics.
-
Challenging the Standard of Care: The positive OS and PFS results in a first-line setting against Keytruda, a dominant player in the NSCLC market, suggest that ivonescimab could emerge as a formidable competitor. If approved in the U.S., it could offer a new, potentially superior, treatment option for a large patient population, shifting the treatment paradigm and challenging Merck’s market share.
-
Regulatory Approvals and Market Access: The U.S. PDUFA date of November 14th is a critical juncture. The robust OS data from HARMONi-2 is expected to significantly strengthen the regulatory submission. Successful approval in the U.S. would pave the way for broader market access and commercialization in other key regions where Summit Therapeutics holds rights.
-
Commercial Potential and Market Forecasts: The commercial outlook for ivonescimab appears exceptionally bright. According to a consensus forecast from GlobalData, the parent company of Clinical Trials Arena, ivonescimab is projected to approach mega-blockbuster status by 2032, generating over $9 billion in annual sales. This forecast underscores the market’s anticipation of ivonescimab’s significant impact and its potential to capture a substantial share of the rapidly growing oncology market.
-
Expansion to Other Solid Tumors: The consistent positive outcomes across multiple Phase III trials, including the success in biliary tract cancer, indicate that ivonescimab’s efficacy may extend beyond NSCLC. This opens up opportunities for further development and regulatory submissions in a wider array of solid tumor indications, significantly expanding its market potential and therapeutic reach.
-
Innovation in Bispecific Antibodies: The success of ivonescimab reinforces the growing importance and therapeutic promise of bispecific antibodies in oncology. This class of drugs, with their ability to engage multiple targets simultaneously, offers a sophisticated approach to overcoming complex biological challenges in cancer, such as drug resistance and immune evasion. The continued development and validation of such innovative modalities will be crucial in advancing cancer treatment.
-
Strategic Value for Summit Therapeutics: For Summit Therapeutics, the success of ivonescimab is transformative. The significant upfront and potential milestone payments, along with future royalties, from the partnership with Akeso represent a substantial return on their investment. This drug is poised to become a cornerstone of Summit’s pipeline and a key driver of their future growth.
In conclusion, the achievement of the overall survival endpoint in the HARMONi-2 Phase III trial marks a significant victory for ivonescimab, solidifying its position as a promising new therapeutic agent in the fight against non-small cell lung cancer. With regulatory decisions on the horizon and a strong foundation of clinical data, ivonescimab is well-positioned to make a substantial impact on patient care and redefine treatment standards in the coming years.
About the Author
